公开(公告)号：US07666869B2

公开(公告)日：2010-02-23

申请号：US12000024

申请日：2007-12-07

申请人： Kosuke Yasuda ,  Hiroshi Morimoto ,  Saburo Kawanami ,  Masataka Hikota ,  Takeshi Matsumoto ,  Kenji Arakawa

发明人： Kosuke Yasuda ,  Hiroshi Morimoto ,  Saburo Kawanami ,  Masataka Hikota ,  Takeshi Matsumoto ,  Kenji Arakawa

IPC分类号： A61K31/535 ,  A61K31/425 ,  A61K31/496

CPC分类号： C07D207/404 ,  A61K31/40 ,  A61K31/425 ,  A61K31/44 ,  A61K31/4965 ,  A61K31/497 ,  A61K31/5375 ,  C07D207/16 ,  C07D207/416 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D513/04

摘要： The present invention is to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]: wherein symbols in the formula have the following meanings; A: —CH2— or —S—, B: CH or N, R1: H, a lower alkyl group, etc., X: a single bonding arm, —CO—, -Alk-CO—, —COCH2—, -Alk-O—, —O—CH2—, —SO2—, —S—, —COO—, —CON(R3)—, -Alk-CON(R3)—, —CON(R3)CH2—, —NHCH2—, etc., R3: hydrogen atom or a lower alkyl group, Alk: a lower alkylene group, and R2: (1) a cyclic group which may be substituted, (2) a substituted amino group, etc., provided that when X is —CO—, then B is N, or a pharmaceutically acceptable salt thereof.

摘要翻译： 本发明提供由式[I]表示的脂族含氮的五元环化合物：其中式中的符号具有以下含义： A：-CH 2 - 或-S-，B：CH或N，R 1：H，低级烷基等，X：单键键，-CO-，-Alk-CO-，-COCH2-， AlK-O-，-O-CH 2 - ， - SO 2 - ， - S - ， - COO-，-CON（R 3） - ， - Alk-CON（R 3） - ， - CON（R 3） 等等，R3：氢原子或低级烷基，Alk：低级亚烷基，R2：（1）可以被取代的环状基团，（2）取代的氨基等，条件是当X 是-CO-，则B为N，或其药学上可接受的盐。

公开(公告)号：US20240161935A1

公开(公告)日：2024-05-16

申请号：US18549653

申请日：2022-03-17

申请人： MITSUBISHI TANABE PHARMA CORP

发明人： Yoshiteru USHIROGAWA ,  Fumihiro TAKAHASHI

IPC分类号： G16H70/60 ,  A61B5/00 ,  G16H10/20

CPC分类号： G16H70/60 ,  A61B5/443 ,  G16H10/20

摘要： [Problem] An information processing device capable of predicting a timing of appearing a symptom related to photosensitivity in a patient with photosensitivity, is provided.
[Solution] An information processing device comprising:



an acquisition unit acquires a reference information set including one or more reference information selected from below (a) to (l), in addition an environmental data; and
a generation unit generates, based on the environmental data and the reference information set, a provision information for providing to a predetermined terminal;
(a) a daylight hour until appearing a photosensitivity related symptom
(b) a timing of the photosensitivity related symptom
(c) a grade of the photosensitivity related symptom
(d) PGIC (Patient Global Impression of Change) score
(e) a skin pigment information
(f) a melanin density
(g) a quantity of a protoporphyrin in a blood
(h) a type of a medicine
(i) a prescription quantity of a medicine
(j) Fitzpatrick skin type
(k) PGIS score (Patient Global Impression Severity)
(l) a data acquired by PROMIS (Patient-Reported Outcomes Measurement Information System).

公开(公告)号：US20230355163A1

公开(公告)日：2023-11-09

申请号：US18247015

申请日：2021-09-29

申请人： MITSUBISHI TANABE PHARMA CORP

发明人： Takeshi SAKATA ,  Akiko GOTO ,  Atsushi KATO ,  Manabu HIRAI

IPC分类号： A61B5/00 ,  A61B5/11

CPC分类号： A61B5/4082 ,  A61B5/1124 ,  A61B5/4842 ,  A61B5/112 ,  A61B5/1128

摘要： A neuromuscular disease evaluation device that is less invasive, highly sensitive, quantitative and objective, and capable of easily evaluating neuromuscular diseases. A device for evaluating motor functions related to neuromuscular diseases, comprising: a memory unit storing a reference value for evaluating a predetermined movement, which is calculated based on a position of at least one body part; an analysis unit for identifying a position of a body part of the user by analyzing information based on an image captured of the predetermined movement, including the user's body; and an evaluation unit for evaluating the motor function based on the numerical value calculated based on the position of the body part of the user and the reference value.